Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease

Abstract
No abstract available
Funding Information
  • Genzyme Corporation (Sanofi)
  • Valerion Therapeutics
  • Shire Pharmaceuticals
  • Roche
  • Pfizer
  • Alexion
  • NIH
  • FDA
  • PCORI
  • Genzyme Corporation
  • Sanofi Company
  • Lysosomal Disease Network (U54NS065768)
  • NCATS
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Duke Chancellor's Discovery Program Research Fund
  • Bill and Melinda Gates Foundation (50957)
  • B57 SAIC-Fredrick Inc. (M11-074)
  • Division of Intramural Research
  • Ellison Medical Foundation (AG-NS-0441-08)
  • National Institute of Mental Health (K01MH098126, R01MH097993, RC2MH089915)
  • National Institute of Allergy and Infectious Diseases (1R56AI098588-01A1)
  • National Human Genome Research Institute (U01HG007672)
  • National Institute of Neurological Disorders and Stroke (U01-NS077303, U01-NS053998, RC2NS070344)
  • National Institutes of Health (U01MH105670)
  • National Institute of Allergy and Infectious Diseases Center (U19-AI067854, UM1-AI100645)
  • National Institute on Aging (P30AG028377)